{"protocolSection":{"identificationModule":{"nctId":"NCT00480324","orgStudyIdInfo":{"id":"107625"},"secondaryIdInfos":[{"id":"2015-001543-36","type":"EUDRACT_NUMBER"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants","officialTitle":"Efficacy, Safety, Reactogenicity and Immunogenicity Study of the Lyophilised Formulation of Rotarix Vaccine in Healthy Japanese Infants"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-06-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2009-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11-21","type":"ACTUAL"},"studyFirstSubmitDate":"2007-05-29","studyFirstSubmitQcDate":"2007-05-29","studyFirstPostDateStruct":{"date":"2007-05-30","type":"ESTIMATED"},"resultsFirstSubmitDate":"2010-03-30","resultsFirstSubmitQcDate":"2010-10-21","resultsFirstPostDateStruct":{"date":"2010-11-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-12-27","lastUpdatePostDateStruct":{"date":"2020-01-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus \\[HRV\\] vaccine, given as a 2-dose primary vaccination, in healthy Japanese infants aged approximately 2 months at the time of the first dose and previously uninfected with HRV. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.","detailedDescription":"Combined diphtheria and tetanus toxoids and acellular pertussis (DTPa) and Hepatitis B (HBV) vaccines are allowed to be co-administered along with Rotarix vaccine/Placebo."},"conditionsModule":{"conditions":["Infections, Rotavirus","Rotavirus Vaccines"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":765,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Rotarix Group","type":"EXPERIMENTAL","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.","interventionNames":["Biological: Rotarix"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Rotarix","description":"Two-dose oral vaccination.","armGroupLabels":["Rotarix Group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Two-dose oral administration.","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age"}],"secondaryOutcomes":[{"measure":"Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age"},{"measure":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age"},{"measure":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age"},{"measure":"Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age"},{"measure":"Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","timeFrame":"From Dose 1 up to 2 years of age"},{"measure":"Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration","description":"Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).","timeFrame":"2 months after Dose 2"},{"measure":"Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies","description":"Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.","timeFrame":"2 months after Dose 2"},{"measure":"Number of Subjects Reporting Solicited Symptoms","description":"Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.","timeFrame":"During the 8-day follow-up period after each dose"},{"measure":"Number of Subjects Reporting Unsolicited Adverse Events (AEs)","description":"Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","timeFrame":"During the 31-day follow-up period after each dose"},{"measure":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","timeFrame":"Up to 2 years of age"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male or female infant between, and including, 6 and 14 weeks (42-104 days) of age at the time of the first vaccination.\n* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study\n* Healthy subjects as established by medical history and clinical examination before entering into the study.\n* Written informed consent obtained from the parent or guardian of the subject.\n* Born between a gestation period of 36 and 42 weeks inclusive.\n\nExclusion Criteria:\n\n* Use of any investigational or non-registered product (drug or vaccine) other than the HRV vaccine within 30 days preceding the first dose of HRV vaccine, or planned use during the study period.\n* History of use of experimental rotavirus vaccine.\n* Chronic administration of immunosuppressants or other immune-modifying drugs since birth.\n* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).\n* Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusception.\n* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition determined by the investigator.\n* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.\n* Previous confirmed occurrence of RV GE.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing is required).\n* A family history of congenital or hereditary immunodeficiency.\n* Acute disease at the time of enrolment.\n* Gastroenteritis within 7 days preceding the study vaccine administration.\n* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Weeks","maximumAge":"14 Weeks","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Aichi","zip":"451-0052","country":"Japan","geoPoint":{"lat":32.51879,"lon":130.62158}},{"facility":"GSK Investigational Site","city":"Chiba","zip":"275-8580","country":"Japan","geoPoint":{"lat":35.6,"lon":140.11667}},{"facility":"GSK Investigational Site","city":"Fukuoka","zip":"802-8533","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}},{"facility":"GSK Investigational Site","city":"Hiroshima","zip":"720-8520","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"GSK Investigational Site","city":"Hiroshima","zip":"730-8518","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"GSK Investigational Site","city":"Hiroshima","zip":"730-8798","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"GSK Investigational Site","city":"Hiroshima","zip":"734-8530","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"GSK Investigational Site","city":"Hiroshima","zip":"737-0811","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"GSK Investigational Site","city":"Hokkaido","zip":"003-0021","country":"Japan"},{"facility":"GSK Investigational Site","city":"Hokkaido","zip":"065-0033","country":"Japan"},{"facility":"GSK Investigational Site","city":"Kagawa","zip":"765-8501","country":"Japan","geoPoint":{"lat":34.06667,"lon":131.03333}},{"facility":"GSK Investigational Site","city":"Kanagawa","zip":"247-8533","country":"Japan","geoPoint":{"lat":37.58333,"lon":139.91667}},{"facility":"GSK Investigational Site","city":"Miyagi","zip":"981-3203","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"GSK Investigational Site","city":"Miyagi","zip":"983-8520","country":"Japan","geoPoint":{"lat":26.62566,"lon":128.18236}},{"facility":"GSK Investigational Site","city":"Nagano","zip":"386-8610","country":"Japan","geoPoint":{"lat":36.65,"lon":138.18333}},{"facility":"GSK Investigational Site","city":"Nagasaki","zip":"856-8562","country":"Japan","geoPoint":{"lat":32.75,"lon":129.88333}},{"facility":"GSK Investigational Site","city":"Niigata","zip":"957-8588","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"GSK Investigational Site","city":"Okayama","zip":"701-0204","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"GSK Investigational Site","city":"Okayama","zip":"701-1192","country":"Japan","geoPoint":{"lat":34.65,"lon":133.93333}},{"facility":"GSK Investigational Site","city":"Osaka","zip":"591-8025","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}}]},"referencesModule":{"references":[{"pmid":"21640780","type":"BACKGROUND","citation":"Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine. 2011 Aug 26;29(37):6335-41. doi: 10.1016/j.vaccine.2011.05.017. Epub 2011 Jun 2."},{"type":"BACKGROUND","citation":"Kawamura N et al. Efficacy of Human Rotavirus (G1P[8] strain) Vaccine (HRV) RIX4414 in Japanese Infants during the Two-year Efficacy Follow-up Period. Abstract presented at the 114th Annual Meeting of Japan Pediatric Society (JPS). Tokyo, Japan, 12-14 August 2011."},{"type":"BACKGROUND","citation":"Kawamura N et al. Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point. Abstract presented at the 28th meeting of European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4-8 May 2010."},{"pmid":"24047799","type":"BACKGROUND","citation":"Buyse H, Vinals C, Karkada N, Han HH. The human rotavirus vaccine Rotarix in infants: an integrated analysis of safety and reactogenicity. Hum Vaccin Immunother. 2014;10(1):19-24. doi: 10.4161/hv.26476. Epub 2013 Oct 8."},{"pmid":"34788488","type":"DERIVED","citation":"Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N, Soares-Weiser K. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2021 Nov 17;11(11):CD008521. doi: 10.1002/14651858.CD008521.pub6."}],"seeAlsoLinks":[{"label":"Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.","url":"https://www.clinicalstudydatarequest.com"}],"availIpds":[{"id":"107625","type":"Informed Consent Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Statistical Analysis Plan","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Individual Participant Data Set","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Study Protocol","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Dataset Specification","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Annotated Case Report Form","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"},{"id":"107625","type":"Clinical Study Report","url":"https://www.clinicalstudydatarequest.com","comment":"For additional information about this study please refer to the GSK Clinical Study Register"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"IPD is available via the Clinical Study Data Request site (click on the link provided below)","accessCriteria":"Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.","url":"https://clinicalstudydatarequest.com/Posting.aspx?ID=272"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"FG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"508"},{"groupId":"FG001","numSubjects":"257"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"476"},{"groupId":"FG001","numSubjects":"241"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Subject's mother pregnant","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"BG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"508"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"765"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"weeks","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7.7","spread":"1.99"},{"groupId":"BG001","value":"7.7","spread":"2.05"},{"groupId":"BG002","value":"7.7","spread":"2.01"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"229"},{"groupId":"BG001","value":"134"},{"groupId":"BG002","value":"363"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"279"},{"groupId":"BG001","value":"123"},{"groupId":"BG002","value":"402"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"250"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"34"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Severe Rotavirus (RV) Gastroenteritis (GE) Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"A subject was considered as reporting severe rotavirus gastroenteritis when the subject scored 11 or more on a 20-point scoring system (Vesikari scoring system).","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"250"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of G1 Type","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere RV GE was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"250"}]}],"classes":[{"title":"Any RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}]}]},{"title":"Severe RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rotavirus (RV) Gastroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains of Non-G1 Types","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"250"}]}],"classes":[{"title":"Any RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"21"}]}]},{"title":"Severe RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Hospitalized Due to Rotavirus (RV) Gastroenteritis (GE) Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for efficacy.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From 2 weeks after Dose 2 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"250"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Any Rotavirus (RV) Gatroenteritis (GE) and Severe RV GE Leading to Medical Intervention and Caused by the Circulating Wild-type RV Strains","description":"Rotavirus (RV) gastroenteritis (GE) was defined as an episode of any severity GE leading to a medical intervention occurring at least two weeks after dose 2 in which rotavirus other than vaccine strain is identified in a stool sample collected as soon as possible but preferably not later than 7 days after the start of the episode.\n\nSevere rotavirus gastroenteritis was defined as an episode of rotavirus gastroenteritis with score ≥ 11 on a 20-point scoring system (Vesikari scoring system).","populationDescription":"The analysis was performed on the Total Vaccinated cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"From Dose 1 up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"508"},{"groupId":"OG001","value":"257"}]}],"classes":[{"title":"Any RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"36"}]}]},{"title":"Severe RV GE","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"13"}]}]}]},{"type":"SECONDARY","title":"Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody Concentration","description":"Anti-rotavirus immunoglobulin A antibody concentrations are given as geometric mean concentrations (GMCs). Arbitrary 'zero' values were set in the Placebo Group since the GMC was below the assay cut-off value (20 U/mL).","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units per milliliter (U/mL)","timeFrame":"2 months after Dose 2","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"217.0","lowerLimit":"109.9","upperLimit":"428.6"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Seroconverted for Anti-rotavirus Immunoglobulin A (IgA) Antibodies","description":"Seroconversion was defined as the appearance of anti-rotavirus immunoglobulin A antibody concentration ≥ 20 units (U)/milliliter (mL) in subjects initially (i.e. prior to the first dose of rotarix) seronegative.","populationDescription":"The analysis was performed on the according-to-protocol (ATP) cohort for immunogenicity.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"2 months after Dose 2","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"20"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Solicited Symptoms","description":"Solicited symptoms assessed include cough, diarrhoea, fever, irritability, loss of appetite and vomiting.","populationDescription":"The analysis was performed on the Total Vaccinated cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the 8-day follow-up period after each dose","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"508"},{"groupId":"OG001","value":"257"}]}],"classes":[{"title":"Cough","categories":[{"measurements":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"92"}]}]},{"title":"Diarrhoea","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"14"}]}]},{"title":"Fever","categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"22"}]}]},{"title":"Irritability","categories":[{"measurements":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"125"}]}]},{"title":"Loss of appetite","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"33"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"36"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Unsolicited Adverse Events (AEs)","description":"Unsolicited adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","populationDescription":"The analysis was performed on the Total Vaccinated cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"During the 31-day follow-up period after each dose","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"508"},{"groupId":"OG001","value":"257"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"144"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reporting Serious Adverse Events (SAEs)","description":"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.","populationDescription":"The analysis was performed on the Total Vaccinated cohort.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"subjects","timeFrame":"Up to 2 years of age","groups":[{"id":"OG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule."},{"id":"OG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"508"},{"groupId":"OG001","value":"257"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"44"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Rotarix Group","description":"Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.","seriousNumAffected":72,"seriousNumAtRisk":508,"otherNumAffected":411,"otherNumAtRisk":508},{"id":"EG001","title":"Placebo Group","description":"Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.","seriousNumAffected":44,"seriousNumAtRisk":257,"otherNumAffected":204,"otherNumAtRisk":257}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":508},{"groupId":"EG001","numAffected":4,"numAtRisk":257}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":508},{"groupId":"EG001","numAffected":3,"numAtRisk":257}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":508},{"groupId":"EG001","numAffected":3,"numAtRisk":257}]},{"term":"Respiratory syncytial virus bronchiolitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":508},{"groupId":"EG001","numAffected":3,"numAtRisk":257}]},{"term":"Exanthema subitum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Bronchopneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Otitis media acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":3,"numAtRisk":257}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Gastroenteritis rotavirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Iron deficiency anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Acute tonsilitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Adenovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Enterocolitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":2,"numAtRisk":257}]},{"term":"Kawasaki's disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Laryngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Aplasia pure red cell","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Breath holding","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Croup infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Cryptorchism","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Erythema infectiosum","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Fibroma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Pertussis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Pneumonia respiratory syncytial viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Skull fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Status epilepticus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Subarachnoid haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Subcutaneous abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Teratoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":508},{"groupId":"EG001","numAffected":0,"numAtRisk":257}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]},{"term":"Weight gain poor","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":508},{"groupId":"EG001","numAffected":1,"numAtRisk":257}]}],"otherEvents":[{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":508},{"groupId":"EG001","numAffected":29,"numAtRisk":257}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":508},{"groupId":"EG001","numAffected":25,"numAtRisk":257}]},{"term":"Upper respiratory tract inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":508},{"groupId":"EG001","numAffected":16,"numAtRisk":257}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (Unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":508},{"groupId":"EG001","numAffected":13,"numAtRisk":257}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (unspecified)","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":508},{"groupId":"EG001","numAffected":21,"numAtRisk":257}]},{"term":"Cough","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":184,"numAtRisk":508},{"groupId":"EG001","numAffected":92,"numAtRisk":257}]},{"term":"Diarrhoea","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":43,"numAtRisk":508},{"groupId":"EG001","numAffected":14,"numAtRisk":257}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":508},{"groupId":"EG001","numAffected":22,"numAtRisk":257}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":261,"numAtRisk":508},{"groupId":"EG001","numAffected":125,"numAtRisk":257}]},{"term":"Loss of appetite","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":81,"numAtRisk":508},{"groupId":"EG001","numAffected":33,"numAtRisk":257}]},{"term":"Vomiting","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":74,"numAtRisk":508},{"groupId":"EG001","numAffected":36,"numAtRisk":257}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Sweden","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D012400","term":"Rotavirus Infections"}],"ancestors":[{"id":"D012088","term":"Reoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C492457","term":"RIX4414 vaccine"}]}},"hasResults":true}